Brain-targeted delivery shuttled by black phosphorus nanostructure to treat Parkinson's disease

Xiong, Shiyun; Li, Zhongjun; Liu, Yao; Wang, Qun; Luo, Jingshan; Chen, Xiao‐Jia; Xie, Zhongjian; Zhang, Yuan; Zhang, Han; Chen, Tongkai

doi:10.1016/j.biomaterials.2020.120339

Cited by 68 publications

(69 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PT conversion efficiency (PCE) was calculated to be around 32% (Figure 2e), comparable to that of black phosphorus (31%). [ 19 ] After five cycles of heating and cooling tests, GDY maintained a similar peak‐like pattern of temperature alterations without significant decrease of the highest temperature, suggesting its good resistance to light‐mediated bleaching or degradation (Figure 2f). The exhibited PT characteristics of GDY nanosheets potentiated their usage in local heating for downstream applications in BBB permeation studies.…”

Section: Resultsmentioning

confidence: 91%

“…One of the advantages associated with PT therapy is the intelligent light‐controlled local hyperthermia which facilitates the permeation of BBB. [ 18 ] Similar to previous reports, [ 19 ] a Transwell plate with bEnd.3 cells in the upper chamber was used to evaluate the permeation ability of GDY‐PEG and GDY‐MN independently upon NIR illumination. Our results showed that there was a significant increase of endothelial cell permeability when upper chambers were treated with GDY‐PEG‐Cy7 and exposed to NIR irradiation, as compared to non‐NIR irradiated or PEG‐Cy7 only group (Figure 4e).…”

Section: Resultsmentioning

confidence: 99%

“…[ 18 ] In the study performed on PD mouse model, lactoferrin‐conjugated BP nanosheets successfully shuttled Paeoniflorin through BBB, resulting in a correction of motional dysfunctions and restoration of TH+ neuronal counting. [ 19 ] Despite the structural similarity between BP and graphdiyne (GDY), the possibility of GDY to permeate BBB is yet to be explored.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Synergistic Photothermal and Chemical Therapy by Smart Dual‐Functional Graphdiyne Nanosheets for Treatment of Parkinson's Disease

Liu

Bao

et al. 2021

Advanced Therapeutics

Self Cite

View full text Add to dashboard Cite

Successful treatment of Parkinson's disease (PD) is impeded by limited permeability of the blood brain barrier (BBB) which causes unsatisfactory drug accumulation in the central nervous system (CNS).In the present study, a novel 2D graphdiyne (GDY)-based nanoplatform is utilized for the delivery of minocycline (MN), one drug candidate for PD treatment. These GDY nanosheets are prepared by sonication and exhibit excellent photothermal (PT) conversion ability (≈32%) without obvious toxicity in vitro. MN can be loaded onto GDY by -stacking (≈90%) and near infrared (NIR) irradiation is able to trigger the release of more than 30% of the payload. The BBB permeability of GDY is confirmed in both cellular and animal models. The behavioral defects of PD mice can be corrected after the PT and chemical synergistic treatment performed by GDY, with the dopaminergic neuron counting restored to normal level. Nanosheets-mediated PT treatment exhibits comparable therapeutic effects to that of L-DOPA, a commercialized PD drug. No obvious damage to major organs or circulation system is detected and physiological parameters remain stable during the behavioral study. This GDY-based delivery system can serve as a promising platform for loading chemical drugs targeting neurodegenerative disorders.

show abstract

Section: Resultsmentioning

confidence: 91%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Synergistic Photothermal and Chemical Therapy by Smart Dual‐Functional Graphdiyne Nanosheets for Treatment of Parkinson's Disease

Liu

Bao

et al. 2021

Advanced Therapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, low bioavailability and difficulty in crossing the blood-brain barrier limited paeoniflorin's therapeutic efficacy. In 2020, a kind of paeoniflorin polyamide nanocrystal and a new dosage form containing brain targeting ligand lactoferrin (Lf) and paeoniflorin (Pae) loaded in black phosphorus nanoplates were reported [ 56 , 57 ]. These dosage forms could help paeoniflorin cross the blood-brain barrier and have good biocompatibility and biosafety.…”

Section: Glycosidesmentioning

confidence: 99%

Research Progress on Natural Product Ingredients’ Therapeutic Effects on Parkinson’s Disease by Regulating Autophagy

Sun

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a common neurodegenerative disease in middle-aged and older adults. Abnormal proteins such as α-synuclein are essential factors in PD’s pathogenesis. Autophagy is the main participant in the clearance of abnormal proteins. The overactive or low function of autophagy leads to autophagy stress. Not only is it difficult to clear abnormal proteins but also it can cause damage to neurons. In this article, the effects of natural products ingredients, such as salidroside, paeoniflorin, curcumin, resveratrol, corynoxine, and baicalein, on regulating autophagy and protecting neurons were discussed in detail to provide a reference for the research and development of drugs for the treatment of PD.

show abstract

“…All the drugs except D-Serine pass the Blood Brain Barrier. Except D-Serine all other drug shows Blood Brain Barrier permeability 22 .…”

Section: Evaluation Of Pharmacokinetic Profile Using Admetsarmentioning

confidence: 99%

In Silico Studies Comparing the Adjuvant Therapies Approved for Parkinson’s disease

Kumar

2021

J. Drug Delivery Ther.

View full text Add to dashboard Cite

One of the most common neurodegenerative disorders is Parkinson's disease. The occurrence of Parkinson's disease includes loss of dopaminergic function and loss of motor function. It is characterized by non- motor as well as motor features. The medicine sector has been primarily focusing on developing adjunctive therapy for the treatment of Parkinson's disease in order to improve the efficacy of the drugs and to improve the quality of treatment. This study aims in silico screening of the drugs available for adjunctive therapy of Parkinson’s disease. The pharmacokinetic parameters, potential adverse effects, toxicity studies, biological activity and the structure activity relationships of the drugs were analyzed and summarized. The drugs chosen as adjunctive therapy in the treatment of Parkinson's disease have reported high chances of adverse drug events and require precautions before administration. Although, they are therapeutically effective it is necessary to investigate other available therapies and then conclude their efficacy. Keywords: Adjunct therapy, in silico, Parkinson’s disease, pharmacokinetic study, toxicity profile.

show abstract

Brain-targeted delivery shuttled by black phosphorus nanostructure to treat Parkinson's disease

Cited by 68 publications

References 36 publications

Synergistic Photothermal and Chemical Therapy by Smart Dual‐Functional Graphdiyne Nanosheets for Treatment of Parkinson's Disease

Synergistic Photothermal and Chemical Therapy by Smart Dual‐Functional Graphdiyne Nanosheets for Treatment of Parkinson's Disease

Research Progress on Natural Product Ingredients’ Therapeutic Effects on Parkinson’s Disease by Regulating Autophagy

In Silico Studies Comparing the Adjuvant Therapies Approved for Parkinson’s disease

Contact Info

Product

Resources

About